The Evolution of an Amine Dehydrogenase Biocatalyst for the Asymmetric Production of Chiral Amines

被引:128
作者
Abrahamson, Michael J. [1 ]
Wong, John W. [2 ]
Bommarius, Andreas S. [1 ,3 ]
机构
[1] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA
[2] Pfizer Worldwide Res & Dev, Chem Res & Dev, Groton, CT 06340 USA
[3] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA
基金
美国国家科学基金会;
关键词
amine dehydrogenase; asymmetric catalysis; biocatalysis; chiral amines; directed evolution; PHENYLALANINE DEHYDROGENASE; DIRECTED EVOLUTION; ENZYMES;
D O I
10.1002/adsc.201201030
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The reductive amination of ketones to produce chiral amines is an important transformation in the production of pharmaceutical intermediates. Therefore, industrially applicable enzymatic methods that enable the selective synthesis of chiral amines could be very useful. Using a phenylalanine dehydrogenase scaffold devoid of amine dehydrogenase activity, a robust amine dehydrogenase has been evolved with a single two-site library allowing for the direct production of (R)-1-(4-fluorophenyl)-propyl-2-amine from para-fluorophenylacetone with a kcat value of 6.85s-1 and a KM value of 7.75mM for the ketone substrate. This is the first example of a highly active amine dehydrogenase capable of accepting aliphatic and benzylic ketone substrates. The stereoselectivity of the evolved amine dehydrogenase was very high (>99.8% ee) showing that high selectivity of the wild-type phenylalanine dehydrogenase was conserved in the evolution process. When paired with glucose/glucose dehydrogenase, NADH cofactor can be effficiently regenerated and the reaction driven to over 93% conversion. The broad specificity, high selectivity, and near complete conversion render this amine dehydrogenase an attractive target for further evolution toward pharmaceutical compounds and subsequent application.
引用
收藏
页码:1780 / 1786
页数:7
相关论文
共 42 条
[1]  
Abrahamson M.J., 2012, ANGEW CHEM, V124, P4036, DOI [DOI 10.1002/ANGE.201107813, 10.1002/ange.201107813]
[2]   The strategy of enantiomer patents of drugs [J].
Agranat, Israel ;
Wainschtein, Silvya R. .
DRUG DISCOVERY TODAY, 2010, 15 (5-6) :163-170
[3]   Catalytic Mechanism and Performance of Computationally Designed Enzymes for Kemp Elimination [J].
Alexandrova, Anastassia N. ;
Roethlisberger, Daniela ;
Baker, David ;
Jorgensen, William L. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (47) :15907-15915
[4]  
[Anonymous], 2012, Molecular Cloning: A Laboratory Manual
[5]  
[Anonymous], 2012, ANGEW CHEM INT ED, V51, P3969
[6]   PHENYLALANINE DEHYDROGENASE OF BACILLUS-BADIUS - PURIFICATION, CHARACTERIZATION AND GENE CLONING [J].
ASANO, Y ;
NAKAZAWA, A ;
ENDO, K ;
HIBINO, Y ;
OHMORI, M ;
NUMAO, N ;
KONDO, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1987, 168 (01) :153-159
[7]   In the light of directed evolution: Pathways of adaptive protein evolution [J].
Bloom, Jesse D. ;
Arnold, Frances H. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 :9995-10000
[8]   Directed Evolution of an Enantioselective Enoate-Reductase: Testing the Utility of Iterative Saturation Mutagenesis [J].
Bougioukou, Despina J. ;
Kille, Sabrina ;
Taglieber, Andreas ;
Reetz, Manfred T. .
ADVANCED SYNTHESIS & CATALYSIS, 2009, 351 (18) :3287-3305
[9]  
Breuer M., 2004, ANGEW CHEM, V116, P806, DOI DOI 10.1002/ANGE.200300599
[10]   Analysis of the reactions used for the preparation of drug candidate molecules [J].
Carey, John S. ;
Laffan, David ;
Thomson, Colin ;
Williams, Mike T. .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2006, 4 (12) :2337-2347